Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05841238
PHASE1

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.

Official title: A Multiple Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tablet and Capsule Formulations of LY3502970 in Healthy Overweight and Obese Participants

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

52

Start Date

2023-04-26

Completion Date

2023-11-13

Last Updated

2026-07-10

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

LY3502970

Administered orally.

Locations (3)

LabCorp CRU, Inc.

Daytona Beach, Florida, United States

Labcorp Clinical Research LP

Dallas, Texas, United States

LabCorp CRU, Inc.

Madison, Wisconsin, United States